Amgen Technology (Ireland) UC

Date: 04 March 2025

CHMP Chair
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Subject: Withdrawal of SKOJOY (aflibercept) – **EMEA/ H/ C/ 006551**

Dear CHMP Chairman,

I would like to inform you that, at this point of time, Amgen Technology (Ireland) Unlimited Company has taken the decision to withdraw the application for the duplicate Marketing Authorisation (MAA) of SKOJOY (aflibercept), which was intended to be used in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

This withdrawal is based on a change to the company's marketing strategy for this duplicate MAA and is not related to product's quality or safety.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the European Medicines Agency website.

Yours sincerely,